Skip to Main Content

Paper Details

Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer.
Sci Rep
4
2022
Author NameAffiliation
Erica K BarnellWashington University School of Medicine
Erica K BarnellMcDonnell Genome Institute, Washington University School of Medicine
Zachary L SkidmoreWashington University School of Medicine
Zachary L SkidmoreMcDonnell Genome Institute, Washington University School of Medicine
Kelsy C CottoWashington University School of Medicine
Kelsy C CottoMcDonnell Genome Institute, Washington University School of Medicine
Megan M RichtersWashington University School of Medicine
Megan M RichtersMcDonnell Genome Institute, Washington University School of Medicine
Catrina FronickMcDonnell Genome Institute, Washington University School of Medicine
Meenakshi AnuragDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Robert S FultonMcDonnell Genome Institute, Washington University School of Medicine
Robert S FultonMcDonnell Genome Institute, Washington University School of Medicine
Matthew J EllisDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Obi L GriffithWashington University School of Medicine
Obi L GriffithMcDonnell Genome Institute, Washington University School of Medicine
Obi L GriffithSiteman Cancer Center, Washington University School of Medicine
Obi L GriffithWashington University School of Medicine
Malachi GriffithWashington University School of Medicine
Malachi GriffithMcDonnell Genome Institute, Washington University School of Medicine
Malachi GriffithSiteman Cancer Center, Washington University School of Medicine
Malachi GriffithWashington University School of Medicine
Foluso O AdemuyiwaWashington University School of Medicine
Foluso O AdemuyiwaSiteman Cancer Center, Washington University School of Medicine
  • 1 - 23

Datasets